Project Grant R44CA285177

The National Cancer Institute (NCI) awarded a $665,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Marker Therapeutics Inc., a small disadvantaged biotechnology company, to develop and evaluate their MT-601 multi-tumor associated antigen (MTAA)-specific T-cell therapy for treating non-Hodgkin lymphoma (NHL) patients who have relapsed after CAR T-cell therapy. The 3-year grant supports a Phase 1 clinical study to manufacture and administer MT-601 to NHL patients without other...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) totaling $2,282,666.00 will support research to develop new immunotherapy approaches for acute myeloid leukemia (AML). The researchers aim to generate "stealth" versions of key AML target genes (FLT3, KIT, IL3RA) that are resistant to CAR-T and monoclonal antibody therapies, thereby enabling targeting...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $402,600.00 to develop novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The key products and services to be delivered under this 5-year award include: Testing the efficacy and safety of CAR T-cells targeting the...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,013,623 to March Biosciences Inc. to develop dual-targeting chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL). The key objectives are to engineer partially-matched, donor-derived CAR T-cells targeting the CD5 and CD7 antigens, which are expressed on most T-cell...

This $650,450 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel TCR-engineered CD4+ T cell therapy for the treatment of lung cancer. The funded research project, led by the University of Southern California, aims to: Determine the mechanisms by which the proprietary "MIIC4 TCRM50A-STEM2 T cells" (or IMT-423) eliminate lung cancer cells. Produce GMP-grade master cell bank and viral...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $683,472 to the University of Cincinnati to support the development and clinical testing of a novel small molecule DHODH inhibitor, HOSU-53, for the treatment of acute myeloid leukemia (AML). The research aims to transition HOSU-53 into phase 1 and phase 1b/2 clinical trials, while establishing pharmacodynamic markers and monitoring strategies to enable personalized dosing and track the...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $738,698 to the Beckman Research Institute of the City of Hope to investigate combining targeted alpha therapy (TAT) using anti-CD38 radioimmunotherapy with total marrow irradiation (TMLI) for the treatment of relapsed/refractory acute myelogenous leukemia in patients over 60 years old. The primary objective is to define the maximum tolerated dose and recommended phase 2 dose of...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy targeting the MR1 protein for the treatment of acute myeloid leukemia (AML) and glioblastoma. The key objectives are to 1) assess MR1 expression in primary AML and glioblastoma samples, 2) evaluate the efficacy of the MR1 CAR-T cells in mouse tumor models, and 3) assess the safety of the MR1 CAR-T cells. The proposed work...

The National Cancer Institute (NCI) awarded the Icahn School of Medicine at Mount Sinai a $237,023 Project Grant under the Cancer Biology Research (CFDA 93.396) program to develop a scalable and cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ). This method will jointly capture gene expression, chromatin accessibility, and DNA methylation at the single-cell level, with the goal of identifying and targeting methylation-driven pathways in acute myeloid leukemia (AML). The...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is aimed at developing more effective and durable therapies to treat acute myeloid leukemia (AML), a devastating form of blood cancer. The $1,162,890 award to the University of Colorado-Denver will support research to characterize the molecular phenotypes and therapeutic vulnerabilities of different leukemia-initiating cell (LIC) subtypes, with a focus on monocytic and TP53 mutant subtypes...